We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
SINNOWA MEDICAL SCIENCE & TECH

EUROIMMUN AG

Produces reagents for medical laboratory diagnostics, including test systems for the determination of various antibod... read more Featured Products: More products

Download Mobile App





Euroimmun Presents New EUROArray Dermatomycosis Assay at Lab Fair

By LabMedica International staff writers
Posted on 31 Jan 2019
Print article
Image: The EUROArray Dermatomycosis assay (Photo courtesy of Euroimmun).
Image: The EUROArray Dermatomycosis assay (Photo courtesy of Euroimmun).
Euroimmun (Lübeck, Germany) presented its new EUROArray Dermatomycosis assay at MedLab Middle East 2019, an international platform for laboratory management and medicine held from February 4-7, 2019, in Dubai, UAE. MedLab is the only medical laboratory industry event that offers manufacturers the opportunity to meet a diverse audience of buyers. From distributors to senior end-users, the 2019 edition welcomed over 19,610 medical lab and trade professionals in search of the latest innovations.

At at MedLab Middle East 2019, Euroimmun presented its new EUROArray Dermatomycosis assay, which provides direct detection and differentiation of the most important dermatomycosis pathogens in one test. The assay simultaneously detects 50 dermatophyte species, and provides species identification for 23 of these as well as for six yeasts and moulds. Accurate identification of the disease-causing pathogens enables early, targeted treatment, increasing the chances of therapy success.

The DNA microarray offers an enormous time advantage over classical detection methods such as pathogen culturing and microscopy, taking just three hours rather than weeks. It is particularly useful for detecting dermatophytes that are difficult to cultivate or those that are slow growing and thus likely to be overlooked. The test specifically identifies mixed infections, for example with yeasts and moulds, and aids differentiation of dermatomycoses from other dermatoses such as psoriasis. Moreover, the assay provides high sensitivity even in patients already undergoing therapy.

The EUROArray procedure is extremely easy to perform and does not require in-depth molecular biology knowledge. Ready-to-use reagents and the small number of pipetting steps ensure a minimal workload. The evaluation and interpretation of results as well as the archiving of data are fully automated and thus, objective. The EUROArray Dermatomycosis provides the most comprehensive direct detection of dermatomycosis pathogens currently available commercially, and thus represents a valuable new tool for dermatologists.


Print article

Channels

Molecular Diagnostics

view channel
Image: Histopathology of neurofibrillary tangles in the brain of a patient with Alzheimer`s disease (Bielschowski silver stain) (Photo courtesy of Dimitri P. Agamanolis, MD).

Alzheimer's Disease Subtypes Proposed from Brain Gene Expression Profiles

Alzheimer’s disease (AD) is the most common form of dementia in the elderly, estimated to affect more than 5.8 million individuals in the USA and more than 50 million worldwide, with almost half of individuals... Read more

Industry

view channel
Illustration

Thermo Fisher Acquires Point-of-Care Molecular Diagnostics Provider Mesa Biotech

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has entered into a definitive agreement to acquire Mesa Biotech (San Diego, CA, USA), a privately held molecular diagnostic company, for approximately USD... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.